B
Bull
Bull · 25%MOLN
$3.68
Szenariopreis
$4.500
-0.148 (-3.28%)Zum Schluss
Loading chart…
- High
- 4.670
- Open
- 4.670
- VWAP
- 4.56
- Vol
- 1.55K
- Mkt Cap
- 233.98M
- Low
- 4.500
- Amount
- 7.08K
- EV/EBITDA, TTM
- 0.00
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
AI analysis of Molecular Partners AG (MOLN)
buyMolecular Partners AG (MOLN) is a good buy right now due to its recent positive clinical trial advancements and a strong cash position of approximately $84 million, which is expected to fund operations into late 2027. The stock has shown a 20-day change of +8.17%, reflecting growing investor interest. However, the main risk is its negative earnings per share (EPS) of -0.44 reported in the last earnings, indicating ongoing financial challenges.
Bewertungskennzahlen
The current forward P/E ratio for Molecular Partners AG (MOLN) is 1.70, compared to its 5-year average forward P/E of -1.14.
Alphio AI Price Scenarios for MOLN
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding MOLN
Event-Zeitleiste
News
9.508-25NASDAQ.COMMolecular Partners Reports H1 2026 Financials and Pipeline Progress
9.508-25NewsfilterMolecular Partners Reports Clinical Progress and Financial Results for H1 2026
2.008-04GlobenewswireMolecular Partners Reports Progress on MP0533 Clinical Study
9.007-16NASDAQ.COMMolecular Partners Reports Clinical Progress in Cholangiocarcinoma Study
- 9.007-16Newsfilter
Molecular Partners Advances MP0317 Clinical Trial for Cholangiocarcinoma
MOLN FAQ — answered by Alphio AI
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. It operates in the Healthcare sector.
Molecular Partners AG (MOLN) is a good buy right now due to its recent positive clinical trial advancements and a strong cash position of approximately $84 million, which is expected to fund operations into late 2027. The stock has shown a 20-day change of +8.17%, reflecting growing investor interest. However, the main risk is its negative earnings per share (EPS) of -0.44 reported in the last earnings, indicating ongoing financial challenges.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.